University of Virginia Library

Search this document 

 
 
 
 
 
 
 
 
 
 
 
CONFLICT OF INTEREST EXEMPTION (ADENOSINE THERAPEUTICS)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
expand section
collapse section
 
 
 
 
 
 

CONFLICT OF INTEREST EXEMPTION (ADENOSINE THERAPEUTICS)


The following resolution was adopted:

WHEREAS, the School of Medicine wishes to enter into a sponsored research contract with Adenosine Therapeutics, LLC, a Virginia Corporation, for developing therapeutic agents; and

WHEREAS, George Beller, M.D., Irving Kron, M.D., Joel Linden, Ph.D., Timothy MacDonald, Ph.D., and Gail Sullivan, Ph.D., have disclosed in advance their equity interests of 4%, 6%, 25%, 8% and 4%, respectively, in Adenosine Therapeutics, LLC., and the University's entry into a research agreement with Adenosine Therapeutics, LLC, would thereby expose them to violation of the Conflicts of Interest Act unless approved by the Board as permitted by 2.1-639.6(C)(7) of the Code of Virginia;

RESOLVED that the arrangement with Andenosine Therapeutics, LLC, is approved by the Board of Visitors in order to permit the University to negotiate and enter into a proposed contract for developing therapeutic agents. This approval is granted provided, as required by the law, the faculty file the required annual disclosure statement of personal interests in Andenosine Therapeutics, LLC, the University files the required annual report concerning the contract with the Secretary of the Commonwealth, and the Chair of the Department of Medicine vigilantly oversees application of University resources in the best interests of the University and in accordance with policy.